Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Invested Capital (2022 - 2025)

Historic Invested Capital for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $219.0 million.

  • Taysha Gene Therapies' Invested Capital rose 14661.76% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.0 million, marking a year-over-year increase of 14661.76%. This contributed to the annual value of $111.5 million for FY2024, which is 4882.5% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Invested Capital is $219.0 million, which was up 14661.76% from $248.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Invested Capital ranged from a high of $248.7 million in Q2 2025 and a low of -$37.1 million during Q2 2023
  • For the 4-year period, Taysha Gene Therapies' Invested Capital averaged around $66.3 million, with its median value being $53.8 million (2024).
  • Data for Taysha Gene Therapies' Invested Capital shows a peak YoY increase of 779641.73% (in 2023) and a maximum YoY decrease of 21417.23% (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Invested Capital stood at $949000.0 in 2022, then skyrocketed by 7796.42% to $74.9 million in 2023, then surged by 48.83% to $111.5 million in 2024, then surged by 96.36% to $219.0 million in 2025.
  • Its Invested Capital stands at $219.0 million for Q3 2025, versus $248.7 million for Q2 2025 and $55.1 million for Q1 2025.